论文部分内容阅读
目的近来有研究提示,基质金属蛋白酶(matrix metalloproteinases,MMPs)可能通过调节卵巢内细胞外基质成分的降解和重建,参与多囊卵巢综合征(polycystic ovary syndrome,PCOS)的病理发生。本研究旨在探讨MMP-9在PCOS发病中可能的作用机制。方法采用病例-对照研究,ELISA法检测PCOS患者和正常对照组血清MMP-9及其抑制因子TIMP-1(tissue inhibitor of metalloproteinase-1,TIMP-1),胰岛素样生长因子I(insulin-like growth factor-I,IGF-I)和胰岛素样生长因子结合蛋白1(insulin-like growth factor binding protein-1,IGFBP-1)的蛋白表达水平。结果P-COS患者血清中MMP-9浓度和MMP-9/TIMP-1比值明显高于对照组。在PCOS组,血清IGFBP-1水平与MMP-9呈负相关。结论MMP-9的高表达可能通过调节IGFs的生物利用度参与PCOS的病理发生,其意义和解释需要进一步研究。
Purpose Recent studies suggest that matrix metalloproteinases (MMPs) may participate in the pathogenesis of polycystic ovary syndrome (PCOS) by regulating the degradation and remodeling of extracellular matrix components in the ovary. This study aimed to investigate the possible mechanism of MMP-9 in the pathogenesis of PCOS. Methods A case-control study was conducted. Serum MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and insulin-like growth factor I factor-I, IGF-I) and insulin-like growth factor binding protein-1 (IGFBP-1). Results Serum levels of MMP-9 and MMP-9 / TIMP-1 in P-COS patients were significantly higher than those in controls. In PCOS group, serum IGFBP-1 level was negatively correlated with MMP-9. Conclusion The high expression of MMP-9 may play a role in the pathogenesis of PCOS by regulating the bioavailability of IGFs. The significance and interpretation of MMP-9 need further study.